Tillys (TLYS) Drops 6.59% on January 27

Equities Staff |

Tillys (TLYS) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 6.59% to $6.24, a loss of $-0.44 per share. Starting at an opening price of $6.63 a share, the stock traded between $6.19 and $6.66 over the course of the trading day. Volume was 47,655 shares over 412 trades, against an average daily volume of 114,217 shares and a total float of 28.47 million.

The losses send Tillys down to a market cap of $177.68 million. In the last year, Tillys has traded between $16.99 and $5.72, and its 50-day SMA is currently $6.27 and 200-day SMA is $8.91.

The stock has a P/E Ratio of 15.9.

Tilly's Inc is a growing destination specialty retailer of action sports inspired apparel, footwear and accessories. Its registered trademarks include Ambitious, Blue Crown, Division 7 and Eldon.

Tillys is based out of Irvine, CA and has some 4,500 employees. Its CEO is Edmond S. Thomas.

For a complete fundamental analysis analysis of Tillys, check out Equities.com’s Stock Valuation Analysis report for TLYS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…